LAM Therapeutics, a Guilford, Conn.-based developer of drugs for cancer and rare diseases, closed $58M in Series C financing.
The backers were not disclosed.
The company intends to use the funds to advance its drugs.
Led by Henri Lichenstein, Ph.D., and Dr. Tian Xu, LAM Therapeutics develops precision therapeutics and companion diagnostics for cancer and rare diseases. The company accelerates drug development by deploying technologies including next-gen sequencing, genome editing, chemical genomics, and combinational drug screening, with deep learning to match clinical drugs to new indications.
LAM has advanced two drugs into clinical trials: LAM-001 for lymphangioleiomyomatosis, and LAM-002 for B-cell non-Hodgkin lymphoma, and is preparing to advance LAM-003 into the clinic for hematological malignancies.
LAM Therapeutics is a 4Catalyzer company.